Skip to main content

Advertisement

SpringerLink
Log in

Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) participate in tumorigenesis, and their association with disease outcome is highly controversial. The present study investigates the influence of MMP-1, MMP-9 and TIMP-2 on different clinicopathologic variables and disease-free survival (DFS) of patients with prostate carcinoma.

Methods

Hundred and forty-five cases are included in the study, and levels of MMP/TIMP expressions are assessed in three tissue compartments (i.e., tumor, stroma and normal glands) with immunohistochemistry.

Results

Matrix metalloproteinase-1 expression in tumor cells was associated with lower Gleason scores, pretreatment prostate-specific antigen levels and lower incidence of vascular, perineural and extracapsular invasions. Moreover, MMP-9 positivity and TIMP-2 expression in normal glands were correlated with lower Gleason patterns and early stage at presentation. Expression of MMP in tumor cells and the presence of TIMP-2 in normal glands were associated with better DFS.

Conclusion

Variability of MMP/TIMP expressions from case to case makes it difficult to evaluate their impact on clinical outcome. However, these proteins might be new and promising targets for prostate cancer therapy in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Alonso DF, Skilton G, DeLorenzo MS, Scursoni AM, Yoshiji H, Gomez DE (1998) Histopathologic findings in a highly invasive mouse mammary carcinoma transfected with human tissue inhibitor of metalloproteinase-1. Oncol Rep 5:1083–1087

    PubMed  CAS  Google Scholar 

  • Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727

    Article  PubMed  CAS  Google Scholar 

  • Bendardaf R, Lamlum H, Vihinen P, Ristamaki R, Laine J, Pyrhonen S (2003) Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 65:337–346

    Article  PubMed  CAS  Google Scholar 

  • Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267–283

    Article  PubMed  CAS  Google Scholar 

  • Cardillo MR, Di Silverio F, Gentile V (2006) Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 26:973–982

    PubMed  CAS  Google Scholar 

  • Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T (2008) High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res 146:104–109

    Article  PubMed  CAS  Google Scholar 

  • Davidsen ML, Würtz S, Romer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114–1120

    Article  PubMed  CAS  Google Scholar 

  • DeClerck YA, Alvarez O, Shimada H, Taylor SM, Langley KE (1994) Tissue inhibitors of metalloproteinases: role in tumor progression. Contrib Nephrol 107:108–115

    CAS  Google Scholar 

  • Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  PubMed  CAS  Google Scholar 

  • Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ (2010) Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer 102:922–929

    Article  PubMed  CAS  Google Scholar 

  • Giannelli G, Fransvea E, Marinosci F, Bergamini C, Daniele A, Colucci S, Paradiso A, Quaranta M, Antonaci S (2002) Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun 292:161–166

    Article  PubMed  CAS  Google Scholar 

  • Gil Ugarteburu R, Rivas del Fresno M, González Rodríguez I, González Arriaga P, López Cima F, Fernández Samoano A, Fernández García I, Benito García P, Muruamendiaraz Fernández V, Tardón A (2010) Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch Esp Urol 63:125–132

    Article  PubMed  Google Scholar 

  • Gonzalez Rodriguez I, Rivas del Fresno M, Gil Ugarteburu R, Gonzalez Arriaga P, Lopez Cima F, Fernandez Samoano A, Muruamendiaraz Fernandez V, Fernandez Garcia I, Perez-Carral JR, Tardon A (2010) Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience. Arch Esp Urol 63:119–124

    Article  PubMed  Google Scholar 

  • Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R (1996) High levels of tissue inhibitors metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654–1659

    PubMed  CAS  Google Scholar 

  • Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, Rahkonen O, Laato M (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714–723

    Article  PubMed  CAS  Google Scholar 

  • Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67

    Article  PubMed  CAS  Google Scholar 

  • Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun H-J, Ringert R-H (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160:1914–1918

    Article  PubMed  CAS  Google Scholar 

  • Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Peltaway CA (2000) Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295–2308

    PubMed  CAS  Google Scholar 

  • Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13:1550–1557

    Article  PubMed  CAS  Google Scholar 

  • Lia NG, Shib ZH, Tang YP, Duan JA (2009) Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 16:3805–3827

    Article  PubMed  Google Scholar 

  • Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190–196

    PubMed  CAS  Google Scholar 

  • MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS (1999) Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 80:504–512

    Article  PubMed  CAS  Google Scholar 

  • Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2008) Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 28:145–151

    PubMed  Google Scholar 

  • Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC (2005) Matrix metalloproteases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33:44–50

    Article  PubMed  CAS  Google Scholar 

  • Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M (1996) Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 26:303–309

    Article  PubMed  CAS  Google Scholar 

  • Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G, Dimopoulos C (2001) MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 9:130–137

    Article  PubMed  CAS  Google Scholar 

  • Ohbayashi H (2002) Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 3:409–421

    Article  PubMed  CAS  Google Scholar 

  • Overall CM, Kleifeld O (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239

    Article  PubMed  CAS  Google Scholar 

  • Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221–233

    Article  PubMed  CAS  Google Scholar 

  • Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144–150

    Article  PubMed  CAS  Google Scholar 

  • Pulukuri SM, Rao JS (2008) Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 32:757–765

    PubMed  CAS  Google Scholar 

  • Ree AH, Florenes VA, Berg JP, Malandsmo GM, Nesland JM, Fodstad O (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 3:1623–1628

    PubMed  CAS  Google Scholar 

  • Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall’Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, Srougi M, Leite KR (2011) MMP-9 over expression due to TIMP-1 and RECK under expression is associated with prognosis in prostate cancer. Int J Biol Markers 26:255–261

    PubMed  CAS  Google Scholar 

  • Remacle AG, Noël A, Duggan C, McDermott E, O’Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926–931

    Article  PubMed  CAS  Google Scholar 

  • Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Kallakury BV (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198–205

    Article  PubMed  Google Scholar 

  • Salminen EK, Kallioinen MJ, Ala-Houhala MA, Vihinen PP, Tiitinen SL, Varpula M, Vahlberg TJ (2006) Survival markers related to bone metastases in prostate cancer. Anticancer Res 26:4879–4884

    PubMed  CAS  Google Scholar 

  • Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R (2004) Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 444:518–526

    Article  PubMed  CAS  Google Scholar 

  • Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84:1488–1496

    Article  PubMed  CAS  Google Scholar 

  • Seitz C, Djavan B (2006) Biological markers of prostate cancer. Ann Urol 40:329–335

    Article  CAS  Google Scholar 

  • Stratton M, Dalkin B, Nagle R, Ranger-Moore J, Ahmann F, Bowden G (2006) Matrix metalloproteinase-7 in prostatic fluid versus serum PSA for diagnosis of prostate cancer. In: Prostate cancer symposium general poster session A, ASCO, 24–26 February 2006

  • Trudel D, Fradet Y, Meyer F, Harel F, Têtu B (2008) Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39:731–739

    Article  PubMed  CAS  Google Scholar 

  • Trudel D, Fradet Y, Meyer F, Têtu B (2010) Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol 41:1694–1701

    Article  PubMed  CAS  Google Scholar 

  • Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287–297

    Article  PubMed  CAS  Google Scholar 

  • Wilson MJ, Jiang A, Wiehr C, Wang X, Sinha AA, Pei D (2004) Limited processing of pro-matrix metalloprotease-2 (gelatinase A) over expressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. J Androl 25:274–285

    PubMed  CAS  Google Scholar 

  • Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154

    PubMed  CAS  Google Scholar 

  • Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC (2005) Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 354:91–99

    Article  PubMed  CAS  Google Scholar 

  • Yoon JH, Choi YJ, Lee SG (2012) Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol 679:24–33

    Article  PubMed  CAS  Google Scholar 

  • Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN (2008) CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75:230–236

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pathology, Istanbul University Cerrahpasa Medical School, 34098, Kocamustafapasa/Istanbul, Turkey

    Ferhat Ozden, Haydar Durak & Hilal Aki

  2. Istanbul University Cerrahpasa Medical School, 34098, Kocamustafapasa/Istanbul, Turkey

    Caner Saygin & Didem Uzunaslan

  3. Department of Urology, Istanbul University Cerrahpasa Medical School, 34098, Kocamustafapasa/Istanbul, Turkey

    Bulent Onal

Authors
  1. Ferhat Ozden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caner Saygin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Didem Uzunaslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bulent Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haydar Durak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hilal Aki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hilal Aki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozden, F., Saygin, C., Uzunaslan, D. et al. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol 139, 1373–1382 (2013). https://doi.org/10.1007/s00432-013-1453-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-013-1453-x

Keywords

Search

Navigation